A global leader in the medical device coating industry, Surmodics (SRDX) has been lately in the news and all for the right reasons. Since a few years back, the company has been trying to move away from just being a provider of coating technologies to medical device companies. Instead, the current growth strategy is targeted towards offering whole-product solutions that can target the interventional....More>>>
Deals and Financings
China Renaissance, a Beijing investment bank and VC/PE investor, plans to expand its investment funds operations, climbing from $3 billion assets under management currently to $10 billion over the next three years. At the moment, the company runs two funds: Huaxing Growth Capital, focused on technology, media and entertainment, and Huaxing Healthcare. The company plans....More>>>
On Tuesday, our Under the Radar Moversnewsletter suggested small cap clinical-stage biotechnology stock Threshold Pharmaceuticals (NASDAQ: THLD) as a long trade:
The chart below speaks for itself. After trying to work its way above a ceiling at $0.62 for the past several months, that finally happened today, in earnest. Better still, it’s happened after a strong foundation was laid,....More>>>
Shares of Novavax, Inc. (NASDAQ:NVAX), a clinical-stage biotech developing vaccines, have risen about 10.7% as of 3:05 p.m. EDT on Thursday. A positive response to the company’s earnings pushed the stock up a couple days ago, but Thursday’s bump comes in response to recent insider share purchases.
Earlier Thursday morning Novavax filed a....More>>>
Ligand Pharmaceuticals (NASDAQ:LGND) announced its quarterly earnings results on Tuesday. The biotechnology company reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.98, Bloomberg Earnings reports. The firm had revenue of $56.16 million during the quarter, compared to analysts’ expectations of $43.02 million. Ligand Pharmaceuticals had a net margin....More>>>
ImmunoGen (NASDAQ:IMGN) is up 21.8% at 1:06 p.m. EST on no apparent news. Of course, it’s a biotech, so that’s often par for the course.
One possibility is that day traders are just doing their thing, following the momentum, which pushes the stock price higher. We’ll know in a few days if the share price returns to previous levels.
With hundreds of biotech stocks on the market, who can keep up with them all? Probably no one. What happens as a result is that usually only the biggest biotechs (or the small biotechs getting bought by the biggest biotechs) get a lot of coverage.But sometimes those aren’t the stocks to watch most closely.
You might not have heard too much about Akebia Therapeutics (NASDAQ:AKBA), BioMarin....More>>>
Investment company Parkside Investments, LLC buys iShares Core MSCI EAFE, Alerian MLP, SPDR Select Sector Fund – Consumer Discretionary, iShares Nasdaq Biotechnology Index Fund, Alibaba Group Holding, Platform Specialty Products Corp, SPDR S&P Oil & Gas Explor & Product, SPDR Nuveen Bloomberg Barclays Short Term Municipa, Citigroup Inc, Discovery Communications Inc, sells SPDR....More>>>
It has been over two years since I wrote Acceleron Pharma (XLRN) Has Two Potential Blockbusters, so an update is in order. Back then, on July 22, 2015, Acceleron closed at $32.18. It has been very volatile in the meantime, hitting $50.49 on December 29, 2015, but also $21.99 on October 13, 2015. That is part of the thrill (or opportunity, or danger) of investing in clinical-state biotechnology companies.....More>>>
Shares of Dynavax Technologies (DVAX) have fallen by 17% over the past three years. Year-to-date the stock is in the red by around 8% and is also currently our biggest laggard in the Core Biotech model account.
Long time readers are well aware that I believe the best investment ideas have an easily summarized thesis. Here is ours from the Core Biotech series:
HEPLISAV B appears to....More>>>
Media coverage about Catabasis Pharmaceuticals (NASDAQ:CATB) has trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable.....More>>>
Washington’s increased scrutiny of technology giants could spell trouble for their stocks, if history is any guide.
Technology is the least regulated industry sector, with just 27,000 regulations versus 215,000 for manufacturing and 128,000 for the financial sector, according to Bank of America Merrill Lynch. That light touch could change in the wake of Facebook’s consumer data....More>>>
Midway through trading Tuesday, the Dow traded down 0.13 percent to 24,258.53 while the NASDAQ climbed 0.56 percent to 6,813.36. The S&P also rose, gaining 0.10 percent to 2,642.13.
Leading and Lagging Sectors
On Tuesday, the information technology sector proved to be a source of strength for the market. Leading the sector was strength from Daqo New Energy Corp. (NYSE: DQ) and....More>>>
Last year, Gilead Sciences (NASDAQ:GILD) managed a feat that very few of its peers ever have (or probably ever will): It shed a staggering $40 billion in value without a single top-selling drug going off patent.
GILD Market Cap data by YCharts.
In fact, the biotech actually launched multiple new products last year, such as the HIV medsOdefsey and Descovy, along with the latest addition....More>>>
Welcome to the third edition in our new series, JF’s Core Biotech Buys.
Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day’s close when an article is published. Depending on the size of a reader’s account, buying or selling in smaller increments may be warranted or....More>>>